Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC) (REPLICA)

Ipsen

Status: Active, not recruiting

Conditions: Advanced or Metastatic Renal Cell Carcinoma

Study type: Observational

Funder types: Industry

Identifiers

NCT04106349

A-BE-60000-047

Details and patient eligibility

About

The purpose of this study is to describe the real-life use of Cabometyx® in monotherapy or in combination with nivolumab in Belgium in patients with advanced or metastatic Renal Cell Carcinoma (1st, 2nd and later lines of treatment)

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or females aged 18 years and older
• Patients scheduled to receive Cabometyx® in monotherapy or in combination with nivolumabfor advanced or metastatic renal cell carcinoma
• Decision to treat patients with Cabometyx® in monotherapy or in combination with nivolumab has to be taken prior to and independent from participation in the clinical study
• Provision of written informed consent

Exclusion criteria

• Participation in another interventional clinical study at the same time
• Previous participation in this clinical study

Trial design

150 participants in 3 patient groups

1st line

2nd line

later lines